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Abstract
Background: The immunosuppressive mammalian target of rapamycin (mTOR) inhibitors are widely used in solid organ
transplantation, but their effect on kidney disease progression is controversial. mTOR has emerged as one of the main
pathways regulating cell growth, proliferation, differentiation, migration, and survival. The aim of this study was to analyze
the effects of delayed inhibition of mTOR pathway with low dose of everolimus on progression of renal disease and TGFb
expression in the 5/6 nephrectomy model in Wistar rats.
Methods: This study evaluated the effects of everolimus (0.3 mg/k/day) introduced 15 days after surgical procedure on
renal function, proteinuria, renal histology and mechanisms of fibrosis and proliferation.
Results: Everolimus treated group (EveG) showed significantly less proteinuria and albuminuria, less glomerular and
tubulointerstitial damage and fibrosis, fibroblast activation cell proliferation, when compared with control group (CG), even
though the EveG remained with high blood pressure. Treatment with everolimus also diminished glomerular
hypertrophy. Everolimus effectively inhibited the increase of mTOR developed in 5/6 nephrectomy animals, without
changes in AKT mRNA or protein abundance, but with an increase in the pAKT/AKT ratio. Associated with this inhibition,
everolimus blunted the increased expression of TGFb observed in the remnant kidney model.
Conclusion: Delayed mTOR inhibition with low dose of everolimus significantly prevented progressive renal damage and
protected the remnant kidney. mTOR and TGFbmRNA reduction can partially explain this anti fibrotic effect. mTOR can be a
new target to attenuate the progression of chronic kidney disease even in those nephropathies of non-immunologic origin.
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Introduction
In the last few years, mTOR inhibitors such as rapamycin or its
derivative everolimus are increasingly used as potent immunosup-
pressants in renal and cardiac transplant therapy [1].
Chronic allograft nephropathy (CAN) is the main cause of renal
allograft loss after one year of transplantation. Despite the impact
of modern immunosuppression on reducing acute graft rejection,
there has been little impact in long term graft survival [2,3]. Some
investigators propose that mTOR inhibitors can contribute on
reducing CAN progression [4].
Although the pathogenesis of chronic damage responsible for
CAN is still largely unclear both immune and non-immune
mechanisms may participate and they are characterized by an
inflammatory response and the subsequent release of profibrotic
cytokines and growth factor within the kidney [5]. Chronic
interstitial fibrosis, tubular atrophy, vascular occlusive changes and
glomerulosclerosis are the common final pathway leading to
progressive renal dysfunction and to end stage renal failure [6].
Profibrotic mediators such as TGFb mainly produced by epithelial
cells, may prime their transdifferentiation into fibroblasts and their
subsequent activation, directly leading to interstitial fibrosis [7].
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TGFb also stimulates matrix production and reduces its
degradation. The severity of tubulointerstitial inflammation and
fibrosis have long been considered as crucial determinants in the
pathogenesis of renal fibrosis and in long-term prognosis of both
human and experimental chronic nephropathies regardless of the
initial cause [8,9].
mTOR is a major downstream component in the phosphoino-
sitide 3-kinase pathway (PI3K), and has emerged as one of the main
signalling routes utilized by cells to control their growth, prolifer-
ation, differentiation, migration, organization and survival [10].
In addition to lymphocytes, mTOR inhibitors act as anti
proliferative for several other cell types such as vascular smooth
muscle cells, mesangial, tubular and endothelial cells. Massive
urinary protein excretion has been observed in renal transplant
recipients with CAN after conversion from calcineurin inhibitors
to mTOR inhibitors, especially sirolimus [11]. High range
proteinuria has been observed during sirolimus therapy in patients
who received sirolimus de novo [12,13]. Podocyte injury and focal
segmental glomerulosclerosis have been related to mTOR
inhibition in some patients, but the pathways underlying these
lesions remain hypothetic [14,15].
Controversy exists about the beneficial effects of mTOR
inhibition in experimental nephropathies with some reports
showing that it may be useful to diminish progression [16,17]
and others reporting increase in proteinuria and aggravation of
renal disease [18,19].
The model of mass reduction with right nephrectomy plus
ligation of two branches of the left renal artery (5/6 nephrectomy)
has been extensively used to study renal disease progression. Rats
with 5/6 nephrectomy develop severe hypertension, proteinuria
and progression to end stage renal disease [20–22].
The effect of mTOR inhibitors on disease progression in this
model also is controversial. Diekmann et al [23] have reported that
mTOR inhibitors reduce progression, whereas Vogelbacher et al
[19], using the same experimental model, reported that everolimus
worsened chronic disease progression.
The aim of this study was to analyze the effects of delayed
mTOR inhibition on progression of renal disease in the 5/6
nephrectomy model in Wistar rats, using a low dose of everolimus
introduced 2 weeks after nephrectomy and to evaluate its effects
on fibrosis mediators as TGFb.
Results
Everolimus treatment decreased proteinuria and
albuminuria without changes in blood pressure
Blood pressure, BUN, plasma creatinine, plasma bicarbonate
and proteinuria were significantly lower and creatinine clearance
was significantly higher in sham group (SG) when compared with
control group (CG) and everolimus-treated group (EveG) (table 1).
There were no differences in blood pressure, plasma creatinine
and creatinine clearance in CG vs EveG. Anyway, EveG showed
significant lower proteinuria (142.3694.8 vs 279.36125.3 mg/
day, p,0.05), protein creatinine ratio (14.4568.48 vs
28.367.47 mg/mg, p,0.05) and urine albumin (6.8364.6 vs
12.964.9 mg/ml, p,0.05) than CG (table 1).
Everolimus diminished glomerulosclerosis and
tubulointerstitial damage in the remnant kidney
Histological analysis showed less glomerulosclerosis (GS) in
EveG compared with CG when evaluated with PAS stain
(0.360.43 vs. 1.460.73, p,0.05), and with Masson’s stain
(0.4760.45 vs. 1.2560.8, p,0.05). There was also less tubuloin-
terstitial (TI) damage in EveG compared with CG (2.4661.49 vs.
6.5361.07, p,0.05) in PAS stain and in Masson’s stain (0.160.09
vs. 0.2460.16, p,0.05) (Figure 1 and table 2).
Proteinuria is related with the magnitude of tubulointerstitial
(TI) damage. When we considered all the animals together, the
relationship between proteinuria (mg/day) and TI score, evaluated
by Masson’s stain, showed a regression coefficient of 0.86, (R2
0.73 p,0.05).
Everolimus diminished glomerular hypertrophy,
mesangial fibrosis and tubulointerstitial fibrosis in the
remnant kidney
Renal fibrosis was also assessed by morphometric analysis of
renal tissue stained with Sirius red. Data from morphometric
analysis are given as mean 6 SD and as frequency distribution, as
fibrosis develops in a focal and segmental pattern and its
distribution does not show a gaussian pattern. Figure 2A reveals
that the CG has a more intense staining with Sirius red than the
SG group, being the staining in EveG lower that in CG.
Frequency distribution of glomerular area shows that SG have
the cross-sectional area of all the glomeruli assessed grouped
10000 mm2, whereas CG and EveG showed a wider distribution,
with almost all values over 12000 mm2 (Figure 2b).
The CG showed a higher glomerular area than the SG
(2140566612 vs 1055361985 mm2, p,0.05) whereas treatment
with everolimus significantly diminished glomerular hypertrophy
(1813265056 mm2) although it remained significantly higher than
the SG (p,0.05) (fig. 2b).
Figure 2c reveals that data of glomerular (mesangial) fibrosis in
the SG group was grouped around 200 mm2 whereas data of
mesangial fibrosis in CG group showed a widespread distribution
with higher values, and data from the EveG showed more grouped
data around 400 mm2. Statistical analysis reveals that the CG
showed more mesangial fibrosis than the SG (1153.76566.2 vs
185.66104.8 mm2 p,0.05). Treatment with everolimus signifi-
cantly diminished mesangial fibrosis when compared with CG
(429.66283.9 vs 1153.76566.2. mm2, p,0.05).
Figure 2d shows that the changes in tubulo-interstitial fibrosis in
the studied groups show changes similar to those observed in
glomerular fibrosis. The CG showed significantly more interstitial
fibrosis than SG (2823.361424.2 vs. 483.56305.1 mm2, p,0.05),
and the group treated with everolimus showed lower interstitial
fibrosis than CG (897.46499.6 mm2, p,0.05) although it was
significantly higher than the SG (p,0.05) (Figure 2).
Table 1. Weight, blood pressure, renal function, proteinuria
and microalbuminuria from animals at week 8 of treatment.
SG CG EveG
n= 7 n= 11 n= 8
Weight, g 360.6628.4 353.3648 355.6626
Blood Pressure, mmHg 125 615 162625* 161625*
Left Kidney weight, g 1.460.2 2.760.8* 2.2560.36*
BUN, mg/dl 2167 49640 40611
Creatininep, mg/dl 0.460.1 0.7860.48 0.6460.13
Cr Cl, ml/min 0.5260.2 0.3460.11* 0.3260.12*
Proteinuria, mg/d 11.3613 279.36125* 142695*{
Albuminuria, mg/ml wo/d 12.964.9 6.8364.6{
uPCR, mg/mg 0.9661.1 28.367.47* 14.4568.48*{
doi:10.1371/journal.pone.0032516.t001
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Figure 1. Immunohistochemistry: fibrosis, cell proliferation and inflamation. Representative results from the different groups are shown:
Sham Group (A,D,G,J), Control Group (B,E,H,K) and Everolimus Group (C,F,I,L). PAS tinction (A,B,C) (magnification 2006), Immunohistochemistry for a
smooth muscle actin (2006) (D,E, F), Glomerular and tubulointerstitial proliferating cell nuclear antigen (PCNA) immunostaining (2006) (G,H,I) and
anti CD68 (4006) (J,K,L). Sections were counterstained with eosin.
doi:10.1371/journal.pone.0032516.g001
Table 2. Histological and immunohistochemistry semiquantitative analysis.
Stains SG CG EveG
n=7 n = 11 n= 8
Periodic Acid-Schiff G 0.0660.09 1.4060.73* 0.3060.43*{
TI 0.0060.00 6.5361.07* 2.4661.49*{
Masson’s trichrome GS 0.0060.00 1.2560.80* 0.4760.45*{
TIF 0.0060.00 0.2460.16* 0.1060.09*{
Sirius Red MF 185.66104. 1153.76566.2* 0.73* 429.66283.9*{
IF 483.56305.1 2823.361424.2 1424.2* 897.46499.6*{
a-Actine G 0.0160.02 0.8660.71* 0.1960.14*{
TI 0.0060.00 2.0660.55* 1.0360.52*{
PCNA G 0.0560.05 6.0065.37* 2.963*{
TI 0.560.5 51.60629,0* 20620*{
CD-68 I NA 5.6863.85 5.0565.48
doi:10.1371/journal.pone.0032516.t002
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Figure 2. Morphometric analysis of glomerular hypertrophy and kidney fibrosis. Panel A. Representative images from histological sections
stained with Sirius red: Sham Group (A), Control Group (B) and Everolimus Group (C) (magnification 2006). Panel B. Glomerular area (media and SD)
and frequency distribution diagram of glomerular area. Panel C. Mesangial fibrosis area (mean and SD) and frequency distribution diagram of
mesangial fibrosis area in the three groups. Panel D. Tubulointerstitial fibrosis area (mean and SD) and frequency distribution diagram of
tubulointerstitial fibrosis area in the three groups. * p,0.05 vs sham group and {p,0.05 vs control group.
doi:10.1371/journal.pone.0032516.g002
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Everolimus diminished the expression of a smooth
muscle actin and cellular proliferation
We evaluated the effect of everolimus on glomerular expression
and TI expression of asmooth muscle actin. The EveG showed less
staining at glomerular level (0.1960.14 vs 0.8660.71, p,0.05)
and TI level (1.0360.52 vs 2.0660.55, p,0.05) when compared
with CG (Figure 1 and table 2).
Glomerular and TI PCNA staining was significantly reduced in
the EveG compared with CG (2.963 vs 665.37, p,0.05) and
(20620 vs 51.6629, p,0.05) respectively (Figure 1).
There were no differences in macrophage infiltration measured
by CD68 staining (Figure 1).
mTOR mRNA increased in the remnant kidney model and
it was attenuated with Everolimus treatment
mTOR mRNA is over expressed more than 4-fold in CG when
compared with SG (3.9561 UR vs 1.1960.7 UR, p,0.05). This
increase is blunted in the EveG (1.261 UR vs GC, p,0.05)
(Figure 3). There were no differences in Akt mRNA among the
three groups (SG: 1.1360.8, CG: 1.560.8 and EveG: 1.260.3).
pAkt/tAkt protein abundance ratio was significantly higher in CG
(151.5617) and EveG (169618.4) than SG (100612, p,0.05) but
without differences among them (Figure 3 and Figure 4).
Everolimus blunted the increased expression of TGFb
observed in the remnant kidney model
TGFb mRNA significantly increased in the CG when
compared with SG (4.762.8 vs 0.860.4 UR, p,0.05). TGFb in
the EveG returned to the SG levels of expression (0.860.4 UR,
p,0.05 vs GC) (Figure 4).
There were no differences in pERK/ERK ratio among the
different groups.
Discussion
Treatment with everolimus 0.3 mg/kg/day for 8 weeks starting
two weeks after 5/6 nephrectomy significantly reduced protein-
uria, albuminuria, glomerular and tubulo-interstitial fibrosis,
fibroblast proliferation and/or activation, and cellular prolifera-
tion.
It also significantly diminished glomerular hypertrophy. Rovira
et al showed that sirolimus treatment before 5/6 nephrectomy
diminished glomerular hypertrophy but the treatment after
nephrectomy was unable to reduce hypertrophy [24]. As far as
we know this is the first evidence that everolimus given after 5/6
nephrectomy reduced glomerular hypertrophy, one of the main
contributors to glomerulosclerosis in this model [24].
As the fibrosis process develops in a focal and segmental pattern
we decided to show the frequency distribution of fibrosis areas in
the tissue (panels b, c and d, figure 2). These graphics allows us to
visualize the magnitude of fibrosis in the different experimental
groups.
There were no differences in renal function between CG and
EveG, probably related with the limited follow up time in our
model. Other authors using a rat model of polycystic kidney
disease were able to show preservation of renal function after
prolonged treatment with rapamycin [25].
We found a fourfold increase in mTOR mRNA expression in
the remnant kidney model compared with SG. Treatment with
everolimus significantly prevented this increase. We can speculate
that this inhibition of mTOR mRNA is related with the known
Figure 3. Western blot and protein abundance ratio for pAkt/
tAkt and pERK/tERK. A) Inmunoblotting analysis for Total Akt 1–2
and phospho-Akt (Ser473); B) Densitometric analysis of pAkt/total Akt:
SG (n = 7), CG (n = 5) and EveG (n = 6); C) Inmunoblotting analysis for
ERK 1/2 and p-ERK (E-4), D) Densitometric analysis of pERK/total ERK. SG
(n = 7), CG (n = 5) and EveG (n = 6). * p,0.05 vs sham group.
doi:10.1371/journal.pone.0032516.g003
Figure 4. mRNA expression for Akt, mTOR and TGF b. Relative mRNA expression levels of Akt, mTOR and TGF b were assessed by real time
quantitative reverse transcriptase-PCR in remnant kidneys of SG (n = 7), CG (n = 5) and EveG (n = 7). *p,0.05 vs sham, **p,0.05 vs CG.
doi:10.1371/journal.pone.0032516.g004
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transcriptional downregulation effect of mTOR inhibition. In this
way mTOR inhibitors prevented the production of new mTOR,
diminishing the amount of mTOR available for new mTOR
complex formation.
The increase in mTOR mRNA in the remnant kidney model
can play a key role in progression of renal disease. mTOR
phosphorylation increases mRNA translation via activation of S6
kinase 1 (S6K1) and inhibition of the eukaryotic initiation factor
4E–binding protein1 (4E-BP1), enhancing protein production and
cell proliferation [26,27].
The well known increase in mRNA TGFbexpression observed
in the remnant kidney model [28,29] is completely blunted by
everolimus. These results contrast with nephrotoxicity models in
normal rats, in which sirolimus increases TGFb [30]. TGFb
inhibition can partially explain the observed anti-fibrotic effects of
everolimus. These results are in accordance with the referred
effects of mTOR inhibition in fibroblast activation by TGFb [27].
Junaid showed, in the 5/6 nephrectomy model, an increase in
mRNA TGFb and protein abundance for TGFb by elisa, when
compared with the sham group. This increase was blocked with
losartan [22].
Recent reports indicate that one of the most relevant
noncanonical TGFb¿ pathways is mTORC1 [31], giving more
relevance to our findings that mTOR inhibition can affect TGFb
production and signalling.
We found a significant increase in pAkt/tAkt(308) ratio in the
CG, consistent with the stimulation off mTOR signaling pathway
and also mTORC2 in this model. Recently Sarbassov showed that
prolonged exposition to rapamycin is able to inhibit mTORC2
[32]. We were not able to show this inhibition as the treatment
with everolimus didn’t modified Akt phosphorilation. One
alternative explanation to Sarbassov’s findings may be that a
prolonged exposition to mTOR inhibitors can reduce mTOR
availability by means of mTOR mRNA reduction.
On the other hand, Vogelbacher et al [19] using the same
experimental model reported that everolimus (2,5 mg/kg/d)
introduced 3 days after nephrectomy worsened chronic disease
progression. These results were the consequence of a markedly
increased fraction of glomeruli with a defective glomerular
architecture in the everolimus group. Everolimus apparently
inhibited the glomerular repair reaction via proliferative activity
inhibition of the glomerular endothelial and mesangial cells and it
was associated with reduced glomerular vascular endothelial
growth factor mRNA and protein abundance [19]. A recent
review [33] highlighted that rapamycin delays recovery and repair
of experimental acute kidney Injury [34] and causes and/or
exacerbates delay graft function [35].
We used a dose of everolimus more than 8 folds lower than
Vogelbacher et al [19]. Dose election was based in preliminary
data using different doses (5, 3, 1 and 0.3 mg/kg/day). The
animals treated with higher doses showed higher mortality rate
and severe adverse effects: diarrhea, weight loss, arrest in wounds
healing, and encapsulated abdominal abscess that were not
observed with 0.3 mg/kg/day.
We believe that the earlier introduction of high dose everolimus
can not only aggravate a pre existent nephropathy but can also
produce a new and more aggressive experimental model of
nephropathy. Letavernier et al., reported that high sirolimus levels
may induce focal and segmental glomerulosclerosis de novo [36].
Our results are in accordance with those reported by other groups
working with the same model. Diekmann et al reported that
animals treated with sirolimus had less glomerulosclerosis,
tubulointerstitial damage and attenuated the increased expression
of renal vascular endothelial growth factor [23]. Nakagawa et al.
described that everolimus administration suppressed smooth
muscle a actin, macrophage infiltration and kidney injury
molecule-1expression in the proximal tubules [37]. Torras et al.
demonstrated a higher glomerular podocin and nephrin expres-
sion and amelioration of glomerular ultrastructural damage in the
rapamycin group [15].
Beneficial effects of mTOR inhibitors were also reported in
anti-thy1 nephritis [17], in experimental membranous nephrop-
athy [38], in adriamycin induced nephropathy [39], in unilateral
obstructive uropathy [40] and in the murine model of renal
polycystic disease [41]. In diabetes induced by streptozotocin [16]
sirolimus treatment produced a reduction of albuminuria and the
expression of renal mTOR and TGFb.
Our findings provide in vivo evidence that everolimus signifi-
cantly prevented progressive renal fibrosis and protected the
remnant kidney in an experimental model of reduced renal mass.
In order to obtain these beneficial effects everolimus should be
administrated after the acute effects of renal ablation and
reparation have taken effect and in a lower dose than previously
described.
The mTOR and TGFb inhibition can partially explain the anti
fibrotic effects produced by everolimus.
This study supports that mTOR can be a possible new target to
attenuate the progression of chronic kidney disease [4].
Methods
Model and experimental design
All the animals were handled according to the Principles of the
Laboratory Animal Care (National Institutes of Health, 1985).
The experimental protocol was approved by the University
Animal Experimental Committee and by the local ethic
committee. The animals were housed in individual cages in a
constant-temperature room with 12:12-h dark-light and free access
to water and food with a normal protein diet (24%). Rats were
anesthetized with sodium thiopental 35 mg/kg i/p for all surgical
procedures.
Male Wistar rats with an initial body weight of 300630 g were
used for this study. Initially, simultaneous systolic blood pressure
and pulse in the awake animal were registered by the tail cuff
method using CVMS-20 software (World Precision Instruments,
Sarasota, FL, USA).
Rats were randomly assigned to 3 groups. Two of these groups
underwent 5/6 nephrectomy by selective ligation of renal artery
branches followed by contra lateral nephrectomy. SG underwent
abdominal incision and manipulation of both kidneys without
excision.
Two weeks after nephrectomy the EveG received everolimus
0.3 mg/kg/day or vehicle for CG, administered by daily gavages
during 8 weeks. Dose election was based in a preliminary study
using different doses (5, 3, 1 and 0.3 mg/kg/day). The animals
treated with higher doses showed higher mortality rate and severe
adverse effects: diarrhea, weight loss, arrest in wounds healing, and
encapsulated abdominal abscess that were not observed with
0.3 mg/kg/day. Meanwhile, recent reports have described the use
of a lower dose of everolimus in order to reduce mortality [42].
Everolimus for oral administration was provided by Novartis
Pharmaceuticals, Inc.
Functional and Histological studies
The rats were assigned to 3 groups: SG (n= 7), CG (n= 11) and
EveG (n= 8). After 8 weeks of treatment 24 hours urine collection
was performed and simultaneous systolic blood pressure and pulse
were registered. The remnant left kidney was immediately
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perfused with phosphate-buffered saline at 4uC and 4% parafor-
maldehyde, and stored for renal morphology and immunohisto-
chemistry studies.
Serum creatinine, BUN, plasma bicarbonate, urinary protein,
albumin, low weight molecular protein excretion and creatinine
clearance were determined.
Sample storage for RNA and protein extraction purposes
We performed the same experimental procedure with three new
groups of animals: SG (n= 7), CG (n= 5) and EveG (n= 7) to
obtain renal tissue for real time RT PCR and Western blot. At
week 8 remnant kidney was perfussed with cold PBS. The kidney
was removed and renal cortex excised, snap-frozen in liquid
nitrogen and stored at 280uC until processing.
Analytical methods
Serum and urinary creatinine were measured by the buffered
kinetic Jaffe reaction. BUN was determined by spectrophotometric
method, plasma bicarbonate with a blood analyzer (ABL 700,
Radiometer, Copenhagen, Denmark) and urinary protein excre-
tion was assayed by the turbidimetric method with sulfosalicylic
acid. Albuminuria and low weight proteinuria were assessed by
High Performance Liquid Cromatography according to Turpei-
nen [43].
Quantification of renal histology
Coronal sections of the kidney were immersion-fixed in
paraformaldehyde solution and embedded in paraffin. Light
microscopy was performed on 4-mm sections of tissue stained with
periodic acid-Schiff’s (PAS) and Masson trichrome reagent (MT)
to assess GS and TI fibrosis. GS was assessed by semi quantitative
analysis of 20 consecutive glomeruli (4006) according to El Nahas
et al [44]. GS was defined as glomeruli with sclerosis or mesangial
expansion and/or focal hyalinosis with tuft adherence. Glomer-
ulosclerosis was graded from 0 to 4 by a semi quantitative score:
grade *0 normal, *1 mesangial expansion/sclerosis involving less
than 25% of the glomerular tuft, *2 moderate GS (25%–50%), *3
severe GS (50%–75%), and grade *4 diffuse GS (more than 75%).
TI damage was evaluated using a semi quantitative analysis of
20 cortical fields (2006) according to Veniant el al [45]. Lesions
were graded from 0 to 4 according to the area with tubulointer-
stitial changes (tubular atrophy, casts, interstitial inflammation,
and fibrosis).
The score index in each rat was expressed as a mean value of all
scores obtained.
All the histological analysis were performed by an observer
unaware of the treatment received by each group.
Morphometric studies
Morphometric studies were performed in sections 5 mm thick
and Sirius Red stained. In brief, images were captured at 20-fold
magnification using a green optical filter (IF 550) and a high-
resolution videocamera (SONY CCD-iris) connected to a light
microscope (Nikon, Eclipse 50i). The evaluation and image
analysis procedures were performed with specific software
[46].(Fibrosis HR. Master Diagnostica. Granada. Spain) as
previously reported [47,48]. As Sirius Red stains collagen fibers,
the program automatically transforms color images in 256 grey
levels images and quantifies the elements of the image, previously
isolated from the background. In the case of glomerular images, it
is necessary to split the corpuscular area by indicating in the
monitor where the glomerulus is located. Then the program
automatically discriminates the area of renal corpuscles which is
usually surrounded by a pericapsular coat of fibers that are stained
by Sirius Red.
A total of 25 glomerular images and 10 interstitial images
random fields of renal slides (n = 5 animals per group) were
captured and processed. The values obtained for each image were:
a) glomerular fibrotic area or percentage of Sirius red-stained area
which is contained in Bowman’s capsule, b) renal corpuscular area
and c) interstitial fibrotic area, or percentage of tubulointerstitial
area occupied by Sirius red staining (excluding glomeruli and big
arteries). These values, saved in data ASCII files conveniently
labeled, can be exported to any statistical analyses program and
calculate several parameters that can express the degree of renal
fibrosis and glomerular sclerosis in an objective and quantitative
way.
Quantification of immunohistochemistry
Sections of paraformaldehyde fixed kidney tissues were
processed by indirect immune detection technique with Biotin
streptavidin amplified detection system (BioGenex, San Ramon,
CA, USA) using three primary antibodies: (1) proliferating
nuclear cell antigen (PCNA) (Dako Glostrup, Denmark NP047)
(dilution 1:200), as a marker of cell proliferation, (2) a smooth
muscle actin as a marker of myofibroblast transformation (Dako
Glostrup, Denmark NP025) (dilution 1:100) and (3) CD68 as a
marker of macrophages (Serotec, Oxford,UK MCA341R)
(dilution 1:100). Next, samples were incubated with secondary
antibody conjugated with peroxidase, EnVisionH (DAKO,
Glostrup, Denmark) for 30 minutes and stained with DAB
(EnVisionH, DAKOH, Glostrup, Denmark). Tissues were counter
stained with hematoxilin.
Normal rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) was used as a negative control. Mean score per biopsy
was calculated as follows: glomerular PCNA and CD68 as the
mean number of positive cells in 20 glomeruli (cells/glomerular
cross section) (4006), CD68 and PCNA tubular/interstitial score
was obtained as the mean number of stained cells in 20 fields
(cells/fields) (2006).
For the evaluation of a-smooth muscle actin each glomerulus
and tubulointerstitial field was graded semi quantitatively
according to the extent of the staining from 0 (absent) to 4 more
than 75% in the glomerular tuft or more than 75% of
tubulointerstitial field. Mean scores of 20 glomeruli and 20 fields
were calculated. Immunohistochemistry images were acquired
(SnapCool-Pro, NikonH, Tokio, Japon) and digital analysis was
performed (ImagePro-Plus, Versio´n 4.05 Media Cybernetics
Bethesda, MD, USA).
Western Blot Analysis of Akt, phospho-Akt, ERK and
phospho-ERK
Tissue protein extracts were homogenized in lysis buffer
(25 mM HEPES pH7,5, 150 mM NaCl, 1% Igepal CA-630,
10 mM MgCl2, 1 mM EDTA, 10% glycerol, 10 mg/mL aproti-
nin, 10 mg/mL leupeptin, 100 mM PMSF, 25 mM NaF, 1 mM
Na3VO4) and centrifuged at 14,000 g for 30 min. Supernatant
was recovered and proteins were quantified. Western blot analysis
was performed as previously described [49]. In brief lysates
(60 mg/lane) were loaded onto SDS-polyacrylamide gels, and the
proteins were transferred to nitrocellulose membranes (Bio-Rad)
by electroblotting. Membranes blocked in TTBS (10 mM Tris
pH 7.5, 150 mM NaCl, 0.1% Tween 20 plus 2% bovine serum
albumin) were incubated overnight at 4uC, as appropriate, with:
anti-Akt1/2 (1:1000, sc-8312, Santa Cruz Biotechnology, Inc.
Santa Cruz, Temecula CA, USA), anti-phospho-Akt (Ser 473)
(1:1000, #9271, Cell Signaling Technologies, Beverly, MA), anti-
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ERK1 (1:2000, sc-94, Santa Cruz Biotechnology, Inc. Santa Cruz
CA, USA) and anti-phospho-ERK (1:1000, sc-7383, Santa Cruz
Biotechnology, Inc. Santa Cruz CA,USA). Membranes were
incubated with corresponding horseradish peroxidase-conjugated
secondary antibody (1:10,000) and were developed using a
chemiluminescent reagent (ECL detection reagent Amersham
Biosciences). Developed signals were recorded on X-ray film
(Fujifilm) for densitometric analysis (Scion Image Frederick,
Maryland USA).
Quantification of renal mTOR, Akt and TGFß1 by
quantitative Real-Time PCR (qRT-PCR)
Total RNA was obtained following the Trizol manufacturer’s
instructions (Invitrogen, Carlsbad). The RNA used for the study
had a 28 s/18 s ratio between 1.8 and 2.0. Total RNA was
reverse-transcribed as follows: 2 mg of RNA were incubated with
1 ml of 50 mM random hexamers followed by RNA denaturaliza-
tion. Then, 56reaction buffer, 0.4 ml of 100 mM dNTP mix, and
MMLV retrotranscriptase 200 u/ml (Ecogen, Langhorne, PA,
USA) were added in a final volume to 20 ml and the reaction was
incubated during 5 min at 25uC, followed by 30 min at 42uC and
5 min at 85uC to stop the reaction. qRT-PCR was performed
using 5 ml of cDNA, primers and the TaqMan probe for Akt (Rn-
00583646_m1), mTOR (Rn-00571541) and TGFb1 (Rn-
00572010_m1). It is directed to locus gene NM 021578 that
codifies for the translated protein NP_067589, precursor of total
TGFb1 (A pplied Biosystems, CA, USA), and the ABI Prism 7700
Sequence Detector. The level of target gene expression was
determined using the DCt method as described [50] normalized to
the Actin control (Applied Biosystems, Madrid, Spain). Results
were expressed as ‘many fold of the unknown sample’ relative to
the reference value (sham group). Triplicates were done in each
experiment. Results are expressed as mean 6 SEM.
Statistical analysis
All data were expressed as Mean 6 SD. One way analysis of
variance and post hoc with Student-Newman–Keuls test was used
to determine the statistical significance. Statistical significance was
defined as P value less than 0.05.
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